Rheumatology 2014
 

Treatment decisions in RA: Can understanding mode of action help us make a better treatment decision?

Symposium by  Bristol-Myers Squibb

Tuesday 29 April 17.45 - 19.45

Room 11B&C


Chair: Professor Robert Moots, University of Liverpool, UK


Aim: The National Institute for Health and Clinical Effectiveness (NICE) has approved a number of biologic agents for the treatment of rheumatoid arthritis (RA) in the UK, providing treatment options with a range of different mechanisms of action (MoA).

This session aims to challenge the way in which health professionals think when choosing which class of biologic to use following failure of conventional DMARDs, and explores the potential impact of different modes of action on treatment outcomes.

Outcome 1:
The audience will be able to better understand the MoAs of different classes of biologics available for RA, and how this insight can help them to individualize treatment.

Outcome 2:
The audience will be able to better understand the latest evidence from drug trials and observational studies of different classes of biologic in RA.

Outcome 3:
The audience will be able to recognize the impact of choosing the most appropriate, effective treatment in order to deliver tight control and improve long-term patient outcomes in RA.

Introduction: The heterogeneous nature of RA

Professor Robert Moots, University of Liverpool, UK


Lecture title 1: Cytokine inhibition: direct regulation of proinflammatory signals  -Professor Ernest Choy, Cardiff University, UK

Lecture title 2: T-cell co-stimulation blockade: the potential to impact early pathophysiology - Professor John Isaacs, Newcastle University, UK

Discussion: chairman and speakers

Can mode of action, combined with clinical evidence, help us decide which biologic to use on a patient-by-patient basis?

Professor Robert Moots, University of Liverpool, UK

Lecture title 3: Understanding the clinical impact of cytokine blockade - Professor Ernest Choy, Cardiff University, UK

Lecture title 4: Understanding the clinical impact of T-cell modulation - Professor John Isaacs, Newcastle University, UK

Discussion: chairman and speakers